The recent surge in investments into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and difficult drug development programs, has fueled what some are calling "High Investor Pharma." While the potential for blockbuster treatments and impressive returns is undeniable, the associated risks are also considerable